Fibroblast Growth Factor Receptor 3 (FGFR3) is a Strong Heat Shock Protein 90 (Hsp90) Client: Implications for Therapeutic Manipulation

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2011 Apr 14

PMID 21487019

Citations 23

Authors

Melanie B Laederich

Catherine R Degnin

Gregory P Lunstrum

Paul Holden

William A Horton

Affiliations

Soon will be listed here.

Abstract

Fibroblast growth factor receptor 3 (FGFR3) is a key regulator of growth and differentiation, whose aberrant activation causes a number of genetic diseases including achondroplasia and cancer. Hsp90 is a specialized molecular chaperone involved in stabilizing a select set of proteins termed clients. Here, we delineate the relationship of Hsp90 and co-chaperone Cdc37 with FGFR3 and the FGFR family. FGFR3 strongly associates with these chaperone complexes and depends on them for stability and function. Inhibition of Hsp90 function using the geldanamycin analog 17-AAG induces the ubiquitination and degradation of FGFR3 and reduces the signaling capacity of FGFR3. Other FGFRs weakly interact with these chaperones and are differentially influenced by Hsp90 inhibition. The Hsp90-related ubiquitin ligase CHIP is able to interact and destabilize FGFR3. Our results establish FGFR3 as a strong Hsp90 client and suggest that modulating Hsp90 chaperone complexes may beneficially influence the stability and function of FGFR3 in disease.

Citing Articles

Identification of a histone deacetylase inhibitor as a therapeutic candidate for congenital central hypoventilation syndrome.

Africano C, Bachetti T, Uva P, Pitollat G, Del Zotto G, Giacopelli F Mol Ther Nucleic Acids. 2024; 35(4):102319.

PMID: 39329148 PMC: 11426119. DOI: 10.1016/j.omtn.2024.102319.

Cell-based screen identifies porphyrins as FGFR3 activity inhibitors with therapeutic potential for achondroplasia and cancer.

Lin Y, Kao H, Chen W, Kao C, Wu J, Chen Y JCI Insight. 2023; 8(22).

PMID: 37824212 PMC: 10721322. DOI: 10.1172/jci.insight.171257.

Chaperone-assisted E3 ligase CHIP: A double agent in cancer.

Kumar S, Basu M, Ghosh M Genes Dis. 2022; 9(6):1521-1555.

PMID: 36157498 PMC: 9485218. DOI: 10.1016/j.gendis.2021.08.003.

HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion.

Li T, Mehraein-Ghomi F, Forbes M, Namjoshi S, Ballard E, Song Q Mol Ther. 2022; 30(4):1610-1627.

PMID: 35151844 PMC: 9077375. DOI: 10.1016/j.ymthe.2022.02.009.

A Cardiac Mitochondrial FGFR1 Mediates the Antithetical Effects of FGF2 Isoforms on Permeability Transition.

Srisakuldee W, Nickel B, Fandrich R, Zhang F, Pasumarthi K, Kardami E Cells. 2021; 10(10).

PMID: 34685716 PMC: 8534529. DOI: 10.3390/cells10102735.

References

Tavormina P, Shiang R, Thompson L, Zhu Y, Wilkin D, Lachman R . Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet. 1995; 9(3):321-8. DOI: 10.1038/ng0395-321. View

Okiyoneda T, Barriere H, Bagdany M, Rabeh W, Du K, Hohfeld J . Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science. 2010; 329(5993):805-10. PMC: 5026491. DOI: 10.1126/science.1191542. View

Lievens P, Roncador A, Liboi E . K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways. J Mol Biol. 2006; 357(3):783-92. DOI: 10.1016/j.jmb.2006.01.058. View

Qing J, Du X, Chen Y, Chan P, Li H, Wu P . Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest. 2009; 119(5):1216-29. PMC: 2673861. DOI: 10.1172/JCI38017. View

Joazeiro C, Wing S, Huang H, Leverson J, Hunter T, Liu Y . The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science. 1999; 286(5438):309-12. DOI: 10.1126/science.286.5438.309. View

Borkovich K, Farrelly F, Finkelstein D, Taulien J, Lindquist S . hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. Mol Cell Biol. 1989; 9(9):3919-30. PMC: 362454. DOI: 10.1128/mcb.9.9.3919-3930.1989. View

Chen H, Ma J, Li W, Eliseenkova A, Xu C, Neubert T . A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell. 2007; 27(5):717-30. PMC: 2094128. DOI: 10.1016/j.molcel.2007.06.028. View

Morishima Y, Wang A, Yu Z, Pratt W, Osawa Y, Lieberman A . CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins. Hum Mol Genet. 2008; 17(24):3942-52. PMC: 2605787. DOI: 10.1093/hmg/ddn296. View

Eswarakumar V, Lax I, Schlessinger J . Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005; 16(2):139-49. DOI: 10.1016/j.cytogfr.2005.01.001. View

10.

Gould C, Kannan N, Taylor S, Newton A . The chaperones Hsp90 and Cdc37 mediate the maturation and stabilization of protein kinase C through a conserved PXXP motif in the C-terminal tail. J Biol Chem. 2008; 284(8):4921-35. PMC: 2643500. DOI: 10.1074/jbc.M808436200. View

11.

Margineantu D, Emerson C, Diaz D, Hockenbery D . Hsp90 inhibition decreases mitochondrial protein turnover. PLoS One. 2007; 2(10):e1066. PMC: 2031825. DOI: 10.1371/journal.pone.0001066. View

12.

Schulte T, Akinaga S, Soga S, Sullivan W, Stensgard B, Toft D . Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones. 1998; 3(2):100-8. PMC: 312953. DOI: 10.1379/1466-1268(1998)003<0100:arbttn>2.3.co;2. View

13.

Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F . 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med. 2005; 11(10):1088-95. DOI: 10.1038/nm1298. View

14.

Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y . New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res. 2010; 16(10):2792-802. DOI: 10.1158/1078-0432.CCR-09-3112. View

15.

Vecchione A, Cooper H, Trim K, Akbarzadeh S, Heath J, Wheldon L . Protein partners in the life history of activated fibroblast growth factor receptors. Proteomics. 2007; 7(24):4565-78. DOI: 10.1002/pmic.200700615. View

16.

Guo C, Degnin C, Laederich M, Lunstrum G, Holden P, Bihlmaier J . Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia. Cell Signal. 2008; 20(8):1471-7. PMC: 2675614. DOI: 10.1016/j.cellsig.2008.04.001. View

17.

Bae J, Boggon T, Tome F, Mandiyan V, Lax I, Schlessinger J . Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells. Proc Natl Acad Sci U S A. 2010; 107(7):2866-71. PMC: 2840318. DOI: 10.1073/pnas.0914157107. View

18.

Prince T, Matts R . Definition of protein kinase sequence motifs that trigger high affinity binding of Hsp90 and Cdc37. J Biol Chem. 2004; 279(38):39975-81. DOI: 10.1074/jbc.M406882200. View

19.

VanSlyke J, Musil L . Analysis of connexin intracellular transport and assembly. Methods. 2000; 20(2):156-64. DOI: 10.1006/meth.1999.0933. View

20.

Krejci P, Bryja V, Pachernik J, Hampl A, Pogue R, Mekikian P . FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells. Exp Cell Res. 2004; 297(1):152-64. DOI: 10.1016/j.yexcr.2004.03.011. View